An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients.
An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients.
复制标题
DOI：
10.21037/atm-20-4960
复制
发表时间：
2021-03
影响因子：
--
通讯作者：
Cheng H
中科院分区：
文献类型：
--
作者：
Sun F;Kou H;Wang S;Lu Y;Zhao H;Li W;Zhou Q;Jiang Q;Cheng Y;Yang K;Zhuo L;Xu Y;Wu D;Zhan S;Cheng H
The coronavirus disease 2019 (COVID-19) epidemic has lasted for nearly 4 months by this study was conducted. We aimed to describe drug utilization, disease progression, and adverse drug events of COVID-19. A retrospective, single-center case series study enrolled 165 consecutive hospitalized COVID-19 patients who were followed up until March 25, 2020, from a designated hospital in Wuhan. Patients were grouped by a baseline degree of severity: non-severe and severe. An analytical study of drug utilization, disease progression, and adverse events (AEs) of COVID-19 was conducted. Of the 165 COVID-19 cases, antivirals, antibacterials, glucocorticoids, and traditional Chinese medicine (TCM) were administered to 92.7%, 98.8%, 68.5%, and 55.2% of patients, respectively. The total kinds of drugs administered to the severe subgroup [26, interquartile range (IQR) 18–39] were 11 more than the non-severe subgroup (15, IQR 10–24), regardless of comorbidities. The 2 most common combinations of medications in the 165 cases were ‘antiviral therapy + glucocorticoids + TCM’ (81, 49.1%) and ‘antiviral therapy + glucocorticoids’ (23, 13.9%). Compared with non-severe cases, severe cases received more glucocorticoids (88.5% vs. 66.2%, P=0.02), but less TCM (50.0% vs. 63.3%, P=0.20), and suffered a higher percentage of death (34.6% vs. 7.2%, P=0.001). At the end of the follow-up, 130 (78.8%) patients had been discharged, and 24 (14.5%) died. There were 13 patients (7.9%) who had elevated liver enzymes, and 49 patients (29.7%) presented with worsening kidney function during the follow-up. Of the 165 COVID-19 patients, the fatality rate remained high (14.5%). Drug utilization for COVID-19 was diverse and generally complied with the existing guidelines. Combination regimens containing antiviral drugs might be beneficial to assist COVID-19 recovery. Additionally, liver and kidney AEs should not be ignored.
登录
查看更多内容
DOI：
10.15557/pimr.2020.0003
发表时间：
2020-01-01
影响因子：
3.6
作者：
通讯作者：
--
影响因子：
1.5
作者：
Haverkamp, Wilhelm;Kruesmann, Frank;Arvis, Pierre
通讯作者：
Arvis, Pierre
影响因子：
168.9
作者：
Chen, Huijun;Guo, Juanjuan;Zhang, Yuanzhen
通讯作者：
Zhang, Yuanzhen
中国武汉市 138 例 2019 新型冠状病毒感染肺炎住院患者的临床特征。
影响因子：
120.7
作者：
Wang, Dawei;Hu, Bo;Peng, Zhiyong
通讯作者：
Peng, Zhiyong
影响因子：
39.2
作者：
Levey AS;Stevens LA;Schmid CH;Zhang YL;Castro AF 3rd;Feldman HI;Kusek JW;Eggers P;Van Lente F;Greene T;Coresh J;CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
通讯作者：
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)